A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Clinical Cancer Research|2023Cited by 13
Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysisMichele Bottosso, Valentina Guarneri, Christian Zurlo et al.|The Breast|2025Cited by 6
211P ER-low breast cancer: Evolution from primary tumor to relapse and prognostic impactFederica Miglietta, Maria Vittoria Dieci, Daniela Iannaccone et al.|ESMO Open|2023Cited by 1
Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.Federica Miglietta, Maria Vittoria Dieci, Claudio Vernieri et al.|Journal of Clinical Oncology|2024Cited by 1
Supplementary Figure 1 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Unknown|2023Cited by 0